Psychedelic Alpha

Pα+ is the insider’s guide to the business, policy and science of psychedelics. Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. psychedelicalpha.com/join

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour Read more: psychedelicalpha.com/news/im-all-ab…

AtaiBeckley’s EMP-01 Meets Safety Goal in SAD Trial, but Efficacy Signal Leaves Room for Debate Read more: psychedelicalpha.com/news/p%ce%b1-p…

Some new info inside: 1. Office of Congressional Conduct asked to look into how PATH Caucus psychedelics RfI submissions were handled by a consultancy + psychedelic pharma lobby before staffers. 2. Separate complaint calls for review of whether Krysten Sinema has been lobbying.

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on FDA, Election Year and ‘Ibogaine Exceptionalism’ Psychedelic Alpha’s @Josh__Hardman reports from Washington, D.C. Read more: psychedelicalpha.com/news/psychedel…

Helus Reports Murky Phase 2a GAD Results for Deuterated DMT Analog Read more: psychedelicalpha.com/news/p%ce%b1-p…

AbbVie's bretisilocin has become the first psychedelic to receive Priority Medicines (PRIME) eligibility from the European Medicines Agency

Psilocybin for Smoking Cessation Study Publishes Read more: psychedelicalpha.com/news/p%ce%b1-p…

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour Read more: f.mtr.cool/smftfzqnnd

AtaiBeckley Details Phase 3 Design for 5-MeO-DMT in TRD After ‘Successful’ FDA Meeting Read more: f.mtr.cool/oyvsnpczoz

Psychedelic Alpha turns 6 this month. To mark the occasion, we have completely rebuilt the website: new design, faster performance, better navigation across Bulletins, data products, interviews, and more. Explore the new site: psychedelicalpha.com

@Josh__Hardman, @MichaelHaichin, @Alicelineham and the entire @Psyched_Alpha team have built the de facto source of truth for the industry. They remain underrated in their coverage despite all the well deserved hype and you should absolutely consider subscribing 🙇🏻‍♂️

Josh and his team have always covered this space with the rigor and healthy skepticism it deserves. Easily one of the most value-add subscriptions if you follow $DFTX $CMPS $ATAI $HELP

Pα+ Psychedelic Bulletin #221: - Helus $HELP Reports Murky Phase 2a Results - AtaiBeckley $ATAI Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT in TRD; - Psilocybin for Smoking Cessation Study Published - Other Stories... psychedelicalpha.com/news/p%ce%b1-p…

Our Pα+ Psychedelic Bill Tracker now contains more than 100 psychedelics-related bills at the state and federal level that were introduced in the present legislative session. Explore them now via our website: psychedelicalpha.com/data/psychedel…

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal psychedelicalpha.com/news/ataibeckl…

2 mg Produces Similar Remission to 20 mg in Helus Pharma’s Small Phase 2 Study of Deuterated DMT in Generalised Anxiety Disorder $HELP tumbles on the news.

We spoke with Terence Ching, PhD about his group's approach in psilocybin fro OCD trials. Read the full interview: psychedelicalpha.com/news/psilocybi…

We spoke with Terence Ching, PhD about learnings from Yale's psilocybin for OCD trials. Read the full interview: psychedelicalpha.com/news/psilocybi…

In a recent appearance on the Joe Rogan Experience podcast, U.S. Health and Human Services (HHS) Secretary RFK Jr. discussed the need for 'therapeutic guidelines' to govern the use of psychedelics.